Envestnet Portfolio Solutions Inc. Purchases 8,762 Shares of Zoetis Inc. $ZTS

Envestnet Portfolio Solutions Inc. lifted its position in Zoetis Inc. (NYSE:ZTS) by 17.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 59,257 shares of the company’s stock after purchasing an additional 8,762 shares during the quarter. Envestnet Portfolio Solutions Inc.’s holdings in Zoetis were worth $7,456,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Vanguard Group Inc. lifted its stake in shares of Zoetis by 12.9% in the 4th quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company’s stock valued at $6,011,802,000 after purchasing an additional 5,474,210 shares during the last quarter. Diamond Hill Capital Management Inc. purchased a new position in shares of Zoetis during the third quarter worth approximately $394,010,000. Nordea Investment Management AB lifted its stake in Zoetis by 79.2% in the fourth quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company’s stock worth $622,222,000 after acquiring an additional 2,179,578 shares during the period. Montrusco Bolton Investments Inc. increased its holdings in Zoetis by 256.7% during the fourth quarter. Montrusco Bolton Investments Inc. now owns 2,168,078 shares of the company’s stock valued at $266,888,000 after buying an additional 1,560,314 shares during the period. Finally, Arrowstreet Capital Limited Partnership lifted its stake in shares of Zoetis by 83.4% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 2,697,827 shares of the company’s stock worth $394,746,000 after purchasing an additional 1,227,085 shares during the last quarter. 92.80% of the stock is owned by institutional investors.

Zoetis Trading Up 0.9%

NYSE ZTS opened at $79.64 on Thursday. The firm has a 50 day simple moving average of $109.69 and a 200-day simple moving average of $119.37. The company has a debt-to-equity ratio of 2.80, a quick ratio of 1.91 and a current ratio of 3.15. Zoetis Inc. has a one year low of $72.38 and a one year high of $172.23. The firm has a market cap of $33.39 billion, a price-to-earnings ratio of 13.21, a PEG ratio of 1.29 and a beta of 0.87.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, May 7th. The company reported $1.53 EPS for the quarter, missing the consensus estimate of $1.60 by ($0.07). Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The company had revenue of $2.26 billion for the quarter, compared to analyst estimates of $2.30 billion. During the same period in the previous year, the firm earned $1.48 earnings per share. The company’s revenue for the quarter was up 2.9% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Equities research analysts anticipate that Zoetis Inc. will post 6.88 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on ZTS shares. Stifel Nicolaus set a $105.00 price target on Zoetis in a research note on Friday, May 8th. Leerink Partners reissued a “market perform” rating on shares of Zoetis in a research report on Tuesday, March 10th. BTIG Research reissued a “buy” rating and issued a $160.00 target price on shares of Zoetis in a research report on Thursday, February 26th. UBS Group reduced their price target on shares of Zoetis from $130.00 to $99.00 and set a “neutral” rating for the company in a research report on Friday, May 8th. Finally, JPMorgan Chase & Co. reduced their price target on shares of Zoetis from $190.00 to $130.00 and set an “overweight” rating for the company in a research report on Friday, May 8th. Seven research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $134.75.

Insider Activity

In other news, Director Paul Bisaro acquired 2,000 shares of the firm’s stock in a transaction dated Wednesday, May 13th. The stock was acquired at an average cost of $75.88 per share, with a total value of $151,760.00. Following the completion of the acquisition, the director owned 27,862 shares of the company’s stock, valued at $2,114,168.56. The trade was a 7.73% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Michael B. Mccallister purchased 3,000 shares of the stock in a transaction that occurred on Monday, May 11th. The shares were bought at an average cost of $77.76 per share, for a total transaction of $233,280.00. Following the acquisition, the director owned 24,524 shares of the company’s stock, valued at approximately $1,906,986.24. The trade was a 13.94% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last ninety days, insiders bought 11,650 shares of company stock valued at $886,384. 0.22% of the stock is currently owned by company insiders.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.